USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
RADIX PHARMACEUTICALS, INC.
Address:
13303 Sunny Brooke Place
Room 101
Potomac, MD
Phone:
N/A
URL:
N/A
EIN:
770619931
DUNS:
142006910
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,590,508.00 4
SBIR Phase II $2,843,317.00 3

Award List:

Synthesis and Evaluation of Novel Antimalarial Agents

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this research is to develop drugs that are safe and effective against drug-resistant malaria. Malaria is one of the most common infectious diseases in the world. It affects approximately 300 million people and leads to more than 2 million… More

Pre-Clinical Development of Natural Product Analogues as Antimalarial Agents

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$604,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. SBIR Phase I research and additional work at Radix Pharmaceuticals have… More

Development of Natural Product as Antimalarial Agent

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$299,880.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated an d purified two natural products from the… More

Isolation and Antimalarial Activity of Small Molecules from Ocimum sanctum

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated an d purified two natural products from the… More

Pre-Clinical Evaluation of Antimalarial Natural Products from Carica papaya L.

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$590,628.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated an d purified two natural products from the… More

Preclinical Studies of Natural Product Derivatives as Antimalarial Agents

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$998,181.00
Agency:
HHS
Principal Investigator:
Shuren Zhu – 301-675-3714
Abstract:
DESCRIPTION (provided by applicant): This project focuses on the development of a novel therapeutic agent for preventing and treating P. falciparum malaria. A two-year Phase I research has discovered novel molecules with potent antimalarial activity against both sensitive and resistant malaria… More

Development of Small Molecules as Antiprotozoal Agents

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,240,336.00
Agency:
HHS
Principal Investigator:
Shuren Zhu – 301-675-3714
Abstract:
DESCRIPTION (provided by applicant): The proposed research focuses on the development of novel therapeutic agents for the prevention and treatment of malaria caused by P. falciparum. A previous Phase I project has discovered novel molecules with potent antimalarial activity against both sensitive… More